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stimulation site that does not guarantee that
they were actually stimulating the dorsolateral
prefrontal cortex (DLPC) (Mosimann et al.,
2004).
A small, open study has examined response to
rTMS in treatment resistant VaD (Fabre et al.,
2004). The results demonstrated that five of 11
patients were treatment responders with a drop in
HDRS scores between 10 and 14 points. The mean
HDRS score in the responder group decreased from
24 ± 5.9 to 12.6 ± 5.5 while the six nonresponders
had pretreatment HDRS scores of 24.5 ± 7.2 versus
post treatment 24.8 ± 5.9.
We have recently completed a NIH-sponsored
project on the efficacy of rTMS to treat depressive
disorders associated with cerebrovascular disease.
We conducted two independent experiments
comparing active left DLPC rTMS with sham
stimulation. In the first one, we delivered a total
cumulative dose (TCD) of 12,000 magnetic pulses
while in the second one the TCD was increased to
18,000 magnetic pulses. To our knowledge, these
are the first randomized controlled trials of the
efficacy of rTMS to treat VaD and the largest trial
in LLD.
In Experiment 1, the sham group showed a
13.6% decrease in HDRS-17 scores compared to
33.1% decrease in the TCD-12K group (p = 0.04).
Response rates were 6.7% in the sham group and
33.3% in the active group (p = 0.08) and remission
rates were 6.7% in the sham and 13.3% in the
active group (p = 0.50). In Experiment 2, the sham
group showed a 17.5% decrease in HDRS-17 scores
compared with a 42.4% decrease observed in the
TCD-18K group (p = 0.0001). Response rates were
6.9% in the sham group and 39.4% in the active
group (p = 0.003), and remission rates were 3.5%
in the sham group and 27.3% in the active group
(p = 0.01). The effect size of the difference between
HDRS scores was 0.89 in this group of VaD
patients.
Age had a significant impact on the antide-
pressant response to rTMS. Among older patients
(65 years or more), active rTMS produced
significantly greater reductions of HRSD-17 scores
than sham stimulation only in the group of patients
who received the higher rTMS dose (TCD-18K).
Greater antidepressant response to rTMS was
significantly associated with higher frontal grey
matter volumes. rTMS was safe, well tolerated, and
not associated with cognitive deficits. We need to
emphasize that a higher dose of left DLPC rTMS
was associated with greater antidepressant efficacy.
It is highly probable that we have not yet found an
optimal TCD of rTMS to achieve maximal response
and remission rates in this population.
In summary, there is consistent preliminary
evidence suggesting that rTMS is a safe and effective
antidepressant intervention among patients with
VaD. However, future studies should examine
several important issues. The first issue relates to
the selection of those rTMS stimulation parameters
associated with the higher response and remission
rates that can be achieved by rTMS among
this group of patients. A second issue is the
need to determine whether VaD represents a
subgroup of LLD that shows a greater response to
rTMS or if, after optimization of the stimulation
parameters, LLD patients without evidence of
ischemic damage will show similar response to
rTMS as VaD patients. Finally, if VaD proves to be
more responsive to rTMS than other forms of LLD,
we should investigate the underlying mechanism of
this phenomenon.
Further studies should rely on a multicenter
approach in order to enroll a larger sample of
LLD patients that will allow more meaningful
statistical inferences to be made. In addition, it is
advisable to increase the dose of rTMS significantly,
incorporate state of the art techniques to localize
the stimulation site, adjust the rTMS dose to the
degree of prefrontal atrophy, and optimize the sham
stimulation condition.
Needless to say, LLD is a major health concern
for which we still do not have optimal therapeutic
options. rTMS constitutes a reasonable alternative
considering both efficacy and safety issues. In our
opinion, the available evidence clearly supports the
need for further research in this field.
RICARDO E. JORGE AND ROBERT G. ROBINSON
Department of Psychiatry, Roy J and Lucille A. Carver
College of Medicine, University of Iowa, U.S.A.
Email: Ricardo-jorge@uiowa.edu
Commentary
As we are all well aware, depression in older people
remains one of the great challenges in our field.
Prevalence of major depression in older people is
usually cited as around 3%, but minor depressive
symptoms are up to fivefold more common, may
be as disabling as major depression and carry a
poor prognosis. For example, Chuan et al. (2008)
found that subsyndromal depression had similar
adverse consequences on mental, physical and
functional status as syndromal cases. In a 12 year
follow-up, Andreescu et al. (2008) showed that
minor depressive symptoms were associated with
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future increases in symptoms, especially if subjects
were female or had functional disability. Depressive
symptoms were also more likely to persist over time
in those with greater medical burden. Similarly,
Lyness et al. (2009) showed that older people
with minor and subsyndromal depression had a
sevenfold risk of developing major depression over
the subsequent year.
Despite its high prevalence, current treatments
for depression in late life are arguably still very
limited. The development of new and effective
treatments for depression is especially challenging
as, despite much knowledge about risk factors for
depression, etiology remains essentially unknown
and many of the established risk factors are not
easy to modify, if they can be modified at all.
The translation of treatments from younger adults
to older adults cannot be automatically assumed,
yet the evidence base supporting drug prescribing
for affective disorders in old people is limited. For
example, a recent survey of Old Age Psychiatrists
found that although prescription rates for mood
stabilizing drugs was high, over half of respondents
indicated that lack of scientific evidence was a major
concern when prescribing treatments for mood
disorders in older people (Ephraim and Prettyman,
2009). Although antidepressants are effective in
older people (Raskin et al., 2008), even novel
dual acting agents such as duloxetine show non-
response rates (as defined by greater than a 50%
reduction in HDRS scores) as high as 60% at 8
weeks (Raskin et al., 2008). Better treatments are
desperately needed, especially for those who do
not respond to standard antidepressant treatments.
Electroconvulsive therapy is widely accepted as
an efficacious treatment for late life depression,
although of course there are risks (albeit small) in
older people because of the need for anesthesia.
There is also a powerful anti-ECT lobby which
undoubtedly has had an influence in the varied
prescribing rates for ECT found both over time and
between different countries. The search for a safe
and effective alternative to ECT is therefore of great
importance.
The top-cited paper under discussion (Manes
et al., 2001) is a good example of a pioneering
study in this regard and one that has had significant
impact in the field. The authors applied rapid TMS
(rTMS) (Jorge et al., 2008) to the left dorsal lateral
cortex in depressed subjects finding no significant
benefits (compared to sham treatment) at seven
days’ follow-up. Intriguingly, they found that
responders to treatment had significantly greater
frontal lobe volume than nonresponders, suggesting
that there may be an important interaction between
structural brain abnormalities (which have been well
identified in depression) and response to treatment,
as others have previously shown (O’Brien et al.,
1998; Almeida et al., 2003). As well as providing
an excellent summary of the field and commentary
in their reflection piece, Jorge and Robinson
also describe two new studies of TMS of left
dorsal atrophy frontal cortex compared with sham
stimulation. Although full details, such as subject
details and numbers of subjects, are described
elsewhere (Jorge et al., 2008) the authors report
benefits in terms of decreased HDRS scores
(but not response rates or admission rates) in
Experiment 1 and highly significant benefits of
TMS in terms of reduced HDRS scores, response
rates and remission rates in subjects with depression
associated with cerebrovascular disease. Such a
“vascular depression” has been categorized as a
subtype of depression in older people which may
have a specific clinical and cognitive profile and
implications with regard to treatment. However,
uncertainties about the relevance of vascular
changes and how such people should be identified
remains. As Almeida (2008) points out, vascular
risk factors and cerebrovascular disease are so
common in older people that if these alone are
used to categorize subjects, almost anyone who
develops depression after the age of 65 may be
deemed to have a vascular depression. However,
Jorge and colleagues are to be congratulated for
undertaking one of the few therapeutic studies in
the area, since it is only by further research in this
area that the true significance of vascular factors and
their implications for treatment can be determined.
Their new studies directly result from their original
pioneering TMS top-cited paper.
Intriguingly, in their recent studies, Jorge and
colleagues have found that greater antidepressant
response to rTMS is significantly associated with
higher frontal grey matter volume. This finding is of
interest as it totally replicates their earlier seminal
study. Findings of their recent studies would also
appear to support the use of rTMS in people with
vascular depression. Of course, several questions
remain. What is the appropriate clinical phenotype
(assuming there is one) of VaD to select subjects
for treatment? On what other characteristics should
subjects be selected for treatment? Why is response
greater in those with VaD as opposed to non-
vascular cases, especially since structural brain
changes like frontal atrophy (which are more
common in those with VaD) actually appear to
be associated with poorer response to rTMS? Will
effects of rTMS persist in the longer term and how
should rTMS be used in conjunction with other
therapies for depression, whether pharmacological
or psychological? What is the dose response for
rTMS? The fact that these exciting findings raise
a number of other important scientific questions is
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a testament to the pioneering TMS work of Manes,
Jorge, Robinson and colleagues. The authors are
to be congratulated for following their earlier paper
with larger, better designed, controlled studies and
for tackling the subject of appropriate treatments
for VaD. They conclude in their reflection that
“the available evidence clearly supports the need
of further research in this field”. I fully agree and,
like others, I await the results of such research with
great interest.
JOHN T. O’BRIEN
Deputy Editor International Psychogeriatrics Newcastle
University, Newcastle, U.K.
Email: J.T.O’Brien@ncl.ac.uk
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